Finally, miR-101-3p has been implicated in imatinib sensitivity in CML with high levels sensitizing to imatinib through the downregulation of JAK2 and inhibition of NF-κB target genes [26]. This evidence concerns the gene NFKB1 and chronic myelogenous leukemia, BCR-ABL1 positive.